表紙
企業レポート

PharmaPoint:小児RS ウイルス(RSV) - 現在および将来の市場参入企業

PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players

発行 GlobalData 商品コード 270706
出版日 ページ情報 英文 36 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
PharmaPoint:小児RS ウイルス(RSV) - 現在および将来の市場参入企業 PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players
出版日: 2013年04月30日 ページ情報: 英文 36 Pages
概要

当レポートでは、小児RS ウイルス(RSV)市場で急成長を遂げている企業について調査分析しており、主要企業の現状と発展因子、RSV分野における競合情勢、主要企業プロファイルなどの情報を、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場の見通し

  • 世界市場
    • 予測
    • 発展因子・障壁 - 世界的課題

第4章 現在および将来の企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • AstraZeneca (MedImmune)
    • Novavax

第5章 付録

目次
Product Code: GDHC1010FPR

Abstract

Summary

GlobalData has released its pharma report, "PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing RSV Market. The report identifies and analyses the key companies shaping and driving the global RSV market. The report provides insight into the competitive RSV landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for RSV
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of the RSV sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving the RSV Market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global RSV market landscape? Identify, understand and capitalize

About GlobalData

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst

3. Market Outlook

  • 3.1. US
    • 3.1.1. Forecast
    • 3.1.2. Key Events
    • 3.1.3. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. AstraZeneca (MedImmune)
    • 4.3.2. Novavax

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Number of eligible patients for prophylaxis
    • 5.4.2. Utilization rates of Synagis
    • 5.4.3. Patient share and generic erosion
    • 5.4.4. Weight of high risk infants
    • 5.4.5. Cost per day
    • 5.4.6. Number of prophylaxis days per year
    • 5.4.7. Annual cost of therapy
    • 5.4.8. Patient compliance
    • 5.4.9. Total sales
    • 5.4.10. Drugs Included in Each Therapeutic Class
    • 5.4.11. Launch and Patent Expiry Dates
    • 5.4.12. General Pricing Assumptions
    • 5.4.13. Individual Drug Assumptions
  • 5.5. Physicians and Specialists Included in this Study
  • 5.6. About the Authors
    • 5.6.1. Authors
    • 5.6.2. Epidemiologist
    • 5.6.3. Global Head of Healthcare
  • 5.7. About GlobalData
  • 5.8. Contact Us
  • 5.9. Disclaimer

List of Tables

  • Table 1: US Sales Forecasts ($m) for Synagis, 2012-2022
  • Table 2: Key Events Impacting Sales for RSV Prophylactics in the US, 2012
  • Table 3: Pediatric RSV Market - Drivers and Barriers, 2012
  • Table 4: Key Companies in the Pediatric RSV Prophylactic Market - United States, 2012
  • Table 5: AstraZeneca's RSV Prophylactics Portfolio Assessment, 2013
  • Table 6: AstraZeneca SWOT Analysis, 2012
  • Table 7: Novavax's Pediatric RSV Prophylactics Portfolio Assessment, 2012
  • Table 8: Novavax SWOT Analysis, 2012
  • Table 9: Key Launch Date
  • Table 10: Key Patent Expiries

List of Figures

  • Figure 1: Company Portfolio Gap Analysis in Pediatric RSV, 2012-2022
Back to Top